Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 13, 2024
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled
New long-term Phase 2 data from the Phase 2/3 Orbit study demonstrated continued reduction in fracture rates
Read more at globenewswire.com
